Shots:
- Samsung Bioepis & Harrow have reported interim data from a P-IV post-marketing surveillance study on SB11, a biosimilar version of Lucentis (ranibizumab), conducted in South Korea from May 2022 to May 2026
- The interim analysis incl. 298 of 305 enrolled pts (182 treatment-naïve & 116 switched), with investigator-determined dosing intervals & follow-up through 24wks. after the first dose
- Treatment-naïve pts showed greater improvements in BCVA & CST than switched pts, with mean BCVA changes of -0.10 vs -0.03 & CST changes of -95 vs -53µm. Outcomes did not differ significantly by indication, while shorter disease duration was associated with better visual outcomes
Ref: Globenewswire | Image: Samsung Bioepis & Harrow | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
